GlassScriptPhysician profile
Arya Farahmand
NPI 1598751521
$2,153.01
in general payments reported to CMS, 2019-2025
24 companies · $173 in 2025
The $173 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $588 · 2020: $352 · 2021: $143 · 2022: $91.27 · 2023: $195 · 2024: $611 · 2025: $173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $979.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $978.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $633.97 | 2022-2025 | |
| Lundbeck LLC | $240.30 | 2024 | Vyepti |
| Supernus Pharmaceuticals, INC. | $208.56 | 2019-2020 | |
| Ge Healthcare | $143.01 | 2019-2020 | |
| Greenwich Biosciences, INC. | $128.53 | 2019-2020 | |
| Sk Life Science, INC. | $119.11 | 2020-2023 | |
| Emd Serono, INC. | $103.28 | 2019 | |
| Sunovion Pharmaceuticals INC. | $81.64 | 2019-2020 | |
| Kyowa Kirin, INC. | $74.28 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $45.47 | 2020-2021 | |
| Pfizer INC. | $44.52 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $43.69 | 2024 | Ajovy |
| Biogen, INC. | $41.39 | 2021 | |
| Livanova USA, INC. | $37.76 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $36.73 | 2019-2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $34.58 | 2022 | |
| Harmony Biosciences LLC | $28.57 | 2021 | |
| Akcea Therapeutics, INC. | $25.87 | 2019 | |
| Lilly USA, LLC | $25.22 | 2023 | Amyvid |
| Janssen Pharmaceuticals, INC | $24.80 | 2021 | |
| Neuropace, INC. | $20.46 | 2020 | |
| Allergan, INC. | $11.27 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arya Farahmand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.